Chuanbing Shi

581 total citations
22 papers, 441 citations indexed

About

Chuanbing Shi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Chuanbing Shi has authored 22 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Chuanbing Shi's work include Renal cell carcinoma treatment (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Chuanbing Shi is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Chuanbing Shi collaborates with scholars based in China and Bangladesh. Chuanbing Shi's co-authors include Hao Wen, Baolin Wang, Jie Wang, Zhenyu He, Ning Hou, Pingsheng Chen, Xiaojun Yang, Xiaodong Bu, Xuefeng Gu and Lin Xiong and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and Cancer Letters.

In The Last Decade

Chuanbing Shi

19 papers receiving 429 citations

Peers

Chuanbing Shi

ONCOL

PHARM

Kolsoum Rezaie Kahkhaie Iran

Mayrel Palestino Domínguez Mexico

Darko Castven Germany

Surya Ramachandran India

Pihong Li China

Ronglin Yan China

Zhan‐Qi Cao China

J. Todd Williams United States

Kolsoum Rezaie Kahkhaie Iran

Chuanbing Shi

202 ×0.8

104 ×0.7

58 ×0.9

ONCOL

65 ×1.1

31 ×0.6

PHARM

Citations per year, relative to Chuanbing Shi Chuanbing Shi (= 1×) peers Kolsoum Rezaie Kahkhaie

Countries citing papers authored by Chuanbing Shi

Since Specialization

Citations

This map shows the geographic impact of Chuanbing Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuanbing Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuanbing Shi more than expected).

Fields of papers citing papers by Chuanbing Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuanbing Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuanbing Shi. The network helps show where Chuanbing Shi may publish in the future.

Co-authorship network of co-authors of Chuanbing Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Chuanbing Shi. A scholar is included among the top collaborators of Chuanbing Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuanbing Shi. Chuanbing Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bai, Ming, Ning Li, Xianli Yin, et al.. (2025). An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study. Cancer Letters. 634. 218061–218061.

Miao, Yi, Zhen Wang, Chuanbing Shi, et al.. (2024). Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of Hematology. 103(5). 1635–1642.

Zhang, Yu, et al.. (2024). RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis. Translational research. 269. 14–30. 3 indexed citations

Shi, Chuanbing, et al.. (2024). A New Cuproptosis-Related lncRNAs Model for Predicting the Prognosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma and Experimental Validation of LINC01269. International Journal of General Medicine. Volume 17. 6009–6027.

Zhang, Yu, Chuanbing Shi, Xiuxiu Hu, et al.. (2023). Identifying key genes related to the peritubular capillary rarefaction in renal interstitial fibrosis by bioinformatics. Scientific Reports. 13(1). 19611–19611. 6 indexed citations

Sun, Hui‐Chuan, et al.. (2021). Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. OncoTargets and Therapy. Volume 14. 4859–4865. 3 indexed citations

Gu, Xuefeng, Yuan Mao, Chuanbing Shi, et al.. (2019). <p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>. OncoTargets and Therapy. Volume 12. 7843–7855. 6 indexed citations

Tan, Lin, et al.. (2019). High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer. Bioscience Reports. 39(6). 15 indexed citations

Gu, Xuefeng, Chuanbing Shi, & Wei Zhao. (2019). Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma.. PubMed. 12(6). 2173–2183. 7 indexed citations

10.

Liu, Jing, Yiping Li, Lei Liu, et al.. (2017). Double Knockdown of PHD1 and Keap1 Attenuated Hypoxia-Induced Injuries in Hepatocytes. Frontiers in Physiology. 8. 291–291. 14 indexed citations

11.

Shi, Chuanbing, Xiaojun Yang, Xiaodong Bu, Ning Hou, & Pingsheng Chen. (2017). Alpha B-crystallin promotes the invasion and metastasis of colorectal cancer via epithelial-mesenchymal transition. Biochemical and Biophysical Research Communications. 489(4). 369–374. 40 indexed citations

12.

Zhang, Xiaoyi, Lei Liu, Jing Liu, et al.. (2017). Endothelial cells co‐cultured with renal carcinoma cells significantly reduce RECK expression under chemical hypoxia. Cell Biology International. 41(8). 922–927. 5 indexed citations

13.

Shi, Chuanbing, Xiaogang Dong, Jie Wang, et al.. (2016). Laparoscopic abdomino-perineal resection for patients with anorectal malignant melanoma: a report of 4 cases. Journal of Biomedical Research. 30(5). 436–436. 9 indexed citations

14.

Shi, Chuanbing, Xiaojun Yang, Ning Hou, et al.. (2015). High Rab27A expression indicates favorable prognosis in CRC. Diagnostic Pathology. 10(1). 68–68. 23 indexed citations

15.

Shi, Chuanbing, et al.. (2014). Fecal microbiota transplantation and prednisone for severe eosinophilic gastroenteritis. World Journal of Gastroenterology. 20(43). 16368–16368. 23 indexed citations

16.

Shi, Chuanbing, et al.. (2014). Alpha B-crystallin correlates with poor survival in colorectal cancer.. PubMed. 7(9). 6056–63. 22 indexed citations

17.

Gu, Xuefeng, Wei Zhang, Feng Chang, et al.. (2013). High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinoma.. PubMed. 6(11). 2515–22. 23 indexed citations

18.

Wen, Wei, Chuanbing Shi, Yan Shi, et al.. (2012). A pilot animal and clinical study of autologous blood solution compared with normal saline for use as an endoscopic submucosal cushion. Experimental and Therapeutic Medicine. 4(3). 419–424. 7 indexed citations

19.

He, Zhenyu, et al.. (2011). Upregulation of p53 Expression in Patients with Colorectal Cancer by Administration of Curcumin. Cancer Investigation. 29(3). 208–213. 210 indexed citations

20.

He, Zhen‐Yu, et al.. (2010). The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer. Journal of Biomedical Research. 24(1). 51–57. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact